微管關(guān)聯(lián)蛋白τ(MAPT)多克隆抗體
Polyclonal Antibody to Tau Protein (MAPT)
DDPAC; FTDP-17; MAPTL; MSTD; MTBT1; MTBT2; PPND; Neurofibrillary tangle protein; Microtubule Associated Protein Tau; Paired helical filament-tau; G Protein Beta1/Gamma2 Subunit-Interacting Factor 1
- 編號(hào)UPAB983Hu01
- 物種Homo sapiens (Human，人) 相同的名稱(chēng)，不同的物種。
- 來(lái)源多抗制備
- 宿主兔
- 效價(jià)-
- Ig類(lèi)型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原 RPB983Hu01-微管關(guān)聯(lián)蛋白τ(MAPT)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度0.5mg/ml
- 且適物種Mus musculus (Mouse，小鼠), Sus scrofa; Porcine (Pig，豬)
- 應(yīng)用WB; IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價(jià)格 ¥ 299 ¥ 697 ¥ 996 ¥ 2490 ¥ 9960
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
DAB staining on IHC-P; Samples: Human Liver cancer Tissue; Primary Ab: 10μg/ml Rabbit Anti-Human MAPt Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
-
DAB staining on IHC-P;
Samples: Human Breast cancer Tissue;
Primary Ab: 10μg/ml Rabbit Anti-Human MAPt Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Samples: Human Glioma Tissue;
Primary Ab: 10μg/ml Rabbit Anti-Human MAPt Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Samples: Human Lung cancer Tissue;
Primary Ab: 10μg/ml Rabbit Anti-Human MAPt Antibody
Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Human Glioma Tissue
Primary Ab: 10μg/ml Rabbit Anti-Human MAPT Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Mouse Cerebrum Tissue
Primary Ab: 10μg/ml Rabbit Anti-Human MAPT Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19) -
DAB staining on IHC-P;
Sample: Mouse Spinal cord Tissue
Primary Ab: 10μg/ml Rabbit Anti-Human MAPT Antibody
Control: Used PBS instead of primary antibody
Second Ab: 2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
Western Blot; Sample: Lane1: Porcine Cerebrum lysate; Lane2: U87MG cell lysate Primary Ab: 0.9μg/ml Rabbit Anti-Human MAPT Antibody Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody (Catalog: SAA544Rb19)
-
Western Blot; Sample: Human Hela cell lysate; <br/>Primary Ab: 3μg/ml Rabbit Anti-Human MAPt Antibody<br/>Second Ab: 0.2μg/mL HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody<br/>(Catalog: SAA544Rb19)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)MAPT的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別MAPT。
用法
Western blotting: 0.01-3μg/mL;
Immunohistochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPB983Hu01 | 微管關(guān)聯(lián)蛋白τ(MAPT)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAB983Hu01 | 微管關(guān)聯(lián)蛋白τ(MAPT)多克隆抗體 | WB; IHC |
| URAB983Hu21 | 微管關(guān)聯(lián)蛋白τ(MAPT)重組抗體 | FCM |
| UMAB983Hu23 | 微管關(guān)聯(lián)蛋白τ(MAPT)單克隆抗體 | IHC |
| UMAB983Hu21 | 微管關(guān)聯(lián)蛋白τ(MAPT)單克隆抗體 | IHC |
| UMAB983Hu22 | 微管關(guān)聯(lián)蛋白τ(MAPT)單克隆抗體 | IHC |
| USEB983Hu | 微管關(guān)聯(lián)蛋白τ(MAPT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UMEB983Hu | 微管關(guān)聯(lián)蛋白τ(MAPT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,小樣本) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UHEB983Hu | 微管關(guān)聯(lián)蛋白τ(MAPT)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMB983Hu | 微管關(guān)聯(lián)蛋白τ(MAPT)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| UKSB983Hu01 | 微管關(guān)聯(lián)蛋白τ(MAPT)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Eur Rev Med Pharmacol Sci. | Effect of etanercept and lithium chloride on preventing secondary tissue damage in rats with experimental diffuse severe brain injury [Pubmed:24452937] |
| Pediatria i Medycyna Rodzinna | Wp?yw omdlenia u m?odocianych na st??enie bia?ka tau w surowicy krwi [b09f7df8-1e7d-4665-a2a5-bf54dae0cfe9] |
| Acta Angiologica | Serum microtubule associated protein tau and myelin basic protein as the potential markers of brain ischaemia-reperfusion injury in patients undergoing carotid endarterectomy [AA.2016.0008] |
| Journal of physiology and pharmacology | THE PRESENCE OF TAU PROTEIN IN BLOOD AS A POTENTIAL PROGNOSTIC FACTOR IN STROKE PATIENTS [pubmed:28011949] |
| Acta Angiol | Serum microtubule associated protein tau and myelin basic protein as the potential markers of brain ischaemia-reperfusion injury in patients undergoing carotid endarterectomy [AA.2016.0008] |
| Frontiers in?Aging?Neuroscience | Differential hyperphosphorylation of tau-S199,-T231 and-S396 in organotypic brain slices of Alzheimer mice. A model to study early tau hyperphosphorylation using?… [Pubmed:29725295] |
| Scientific Reports | The potential role of serum tau protein (MAPT), neuronal cell adhesion molecule (NrCAM) and neprilysin (NEP) in neurodegenerative disorders development in?… [] |
